Rigel Pharmaceuticals (RIGL) Scheduled to Post Quarterly Earnings on Tuesday

Rigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) will issue its quarterly earnings data after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.03) per share for the quarter. Parties interested in registering for the company's conference call can do so using this link.

Rigel Pharmaceuticals Price Performance

Shares of RIGL traded up $0.04 during trading hours on Wednesday, hitting $1.09. 746,786 shares of the stock were exchanged, compared to its average volume of 1,329,269. The firm has a market capitalization of $191.19 million, a P/E ratio of -7.27 and a beta of 0.95. The business has a 50-day moving average of $1.33 and a 200-day moving average of $1.20. Rigel Pharmaceuticals has a fifty-two week low of $0.71 and a fifty-two week high of $1.96.

Analyst Ratings Changes

RIGL has been the subject of a number of research reports. Cantor Fitzgerald raised their price target on shares of Rigel Pharmaceuticals from $2.00 to $3.00 and gave the stock a "neutral" rating in a report on Wednesday, March 6th. StockNews.com cut shares of Rigel Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, April 4th. HC Wainwright restated a "buy" rating and issued a $15.00 price target on shares of Rigel Pharmaceuticals in a report on Wednesday, March 6th. B. Riley reiterated a "neutral" rating and set a $1.25 price objective on shares of Rigel Pharmaceuticals in a report on Wednesday, March 6th. Finally, Citigroup lifted their price objective on shares of Rigel Pharmaceuticals from $3.00 to $4.00 and gave the company a "buy" rating in a report on Thursday, March 7th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $5.81.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.